Formoterol (n=26) | Placebo (n=25) | |||
Male | Female | Male | Female | |
Participants | 16 | 10 | 15 | 10 |
Age (years) | 26±6 | 25±4 | 28±8 | 25±3 |
Height (cm) | 183±7 | 168±6 | 182±6 | 168±7 |
Weight (kg) | 77.2±10.1 | 62.8±8.8 | 74.8±7.5 | 62.7±8.2 |
Lean mass (kg) | 64.2±8.5 | 45.4±5.7 | 61.7±6.1 | 45.1±4.9 |
Fat percentage (%) | 13.6±3.8 | 24.9±4.4 | 14.4±3.9 | 25.1±3.6 |
V̇O2max (mL·min−1) | 4830±715 | 3282±623 | 4604±397 | 3163±441 |
V̇O2max (mL·min−1·kg bw−1) | 62.8±5.2 | 52.0±4.5 | 61.8±6.5 | 50.9±6.1 |
Incremental exercise performance# (W) | 408±54 | 285±43 | 391±29 | 289±33 |
Power output eliciting V̇O2max (W) | 391±53 | 270±44 | 377±36 | 277±31 |
FVC (L) | 6.1±1.5 | 4.1±0.5 | 5.4±0.7 | 4.2±0.5 |
FEV1 (L) | 4.8±1.1 | 3.6±0.4 | 4.5±0.5 | 3.5±0.3 |
FEV1/FVC | 0.79±0.07 | 0.87±0.04 | 0.84±0.06 | 0.84±0.06 |
Post-exercise change in FEV1 (%) | −0.6±3.0 | −2.9±4.0 | −1.6±2.1 | −2.7±4.4 |
Change in FEV1 after β2-agonist (%) | 1.1±5.6 | 3.5±3.5 | 4.1±3.2 | 1.2±2.6 |
Data are presented as n or mean±sd. V̇O2max: maximal oxygen consumption; FVC: forced vital capacity; FEV1: forced expiratory volume in 1 s. #: the highest power output achieved during the ramp test to exhaustion.